- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues ; day:22 ; month:2 ; year:2016 ; pages:1-12
International journal of clinical oncology ; (22.2.2016), 1-12
- Urheber
-
Hamanishi, Junzo
- Beteiligte Personen und Organisationen
-
Mandai, Masaki
Matsumura, Noriomi
Abiko, Kaoru
Baba, Tsukasa
Konishi, Ikuo
SpringerLink (Online service)
- DOI
-
10.1007/s10147-016-0959-z
- URN
-
urn:nbn:de:1111-201602237460
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek.
Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hamanishi, Junzo
- Mandai, Masaki
- Matsumura, Noriomi
- Abiko, Kaoru
- Baba, Tsukasa
- Konishi, Ikuo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer